---

Anti-VEGF in Ophthalmology - Comprehensive Notes

1. BASIC SCIENCE FOUNDATION

1.1 What is VEGF?

• VEGFR-1 (Flt-1): Expressed on endothelial cells; acts partly as a decoy receptor, modulating VEGF-A availability
• VEGFR-2 (KDR/Flk-1): The principal signaling receptor - activation triggers endothelial proliferation, migration, and increased permeability
• VEGFR-3: Lymphatic endothelium

1.2 VEGF in Normal Ocular Physiology

• VEGF is constitutively expressed at low levels and is essential for maintaining the choriocapillaris and retinal vasculature
• The balance between pro-angiogenic VEGF and inhibitory mediators - pigment epithelium-derived factor (PEDF) and complement factor H (CFH) - maintains vascular homeostasis
• In the developing fetal retina, hypoxia triggers VEGF production, driving the centrifugal vascularization that begins at the optic disc at 16 weeks of gestation and reaches the temporal periphery by ~1 month postnatally. This normal dependence on VEGF is what makes premature infants vulnerable to retinopathy of prematurity (ROP). (Kanski's Clinical Ophthalmology, 10th ed.)

1.3 Mechanism of Pathological VEGF Upregulation

1. Tissue hypoxia (from ischemia, retinal vein occlusion, diabetic capillary loss, subretinal neovascular membranes) activates Hypoxia Inducible Factor-1 alpha (HIF-1alpha)
2. HIF-1alpha translocates to the nucleus and upregulates VEGF-A gene transcription
3. Secreted VEGF-A binds VEGFR-2 on vascular endothelial cells
4. Downstream signaling via PI3K/Akt and MAPK/ERK pathways triggers:
   • Endothelial cell proliferation
   • Migration and tube formation
   • Increased paracellular permeability (disruption of tight junctions - ZO-1, occludin)
   • Recruitment of circulating endothelial progenitor cells

---

2. ANTI-VEGF AGENTS - PHARMACOLOGY

2.1 Overview

• Povidone-iodine 5% to ocular surface; minimum 3 minutes contact time
• Topical anesthesia ± subconjunctival lidocaine
• Injection at 3.5-4.0 mm from limbus (phakic) or 3.0 mm (pseudophakic/aphakic)
• In the inferotemporal or superotemporal quadrant
• Surgical mask mandatory
• Bilateral injections optimally at separate sessions

2.2 Individual Agents

Ranibizumab (Lucentis)

• Class: Humanized monoclonal antibody Fab fragment (antigen-binding fragment only - no Fc region)
• Molecular weight: ~48 kDa (smaller than bevacizumab, allowing better retinal penetration)
• Mechanism: Non-selectively binds and inhibits ALL isoforms of VEGF-A
• Dose: 0.5 mg in 0.05 mL (AMD, RVO); 0.3 mg (DME in some protocols)
• Origin: Derived from the same parent mouse antibody as bevacizumab (rhuMAb VEGF)
• FDA approvals: Neovascular AMD, diabetic macular edema (DME), macular edema following RVO, diabetic retinopathy
• Half-life (intravitreal): ~9 days
• Dosing regimens:
  • Monthly (highest evidence, best VA gain)
  • PRN (as-needed) - 3 initial monthly loading doses then monitor
  • Treat-and-extend (TAE) - extend interval by 2-week increments when stable
• Key trials: MARINA, ANCHOR, PIER, PRONTO, CATT, IVAN (Wills Eye Manual; Kanski's)

Bevacizumab (Avastin)

• Class: Full-length humanized monoclonal IgG1 antibody (with Fc region)
• Molecular weight: ~149 kDa
• Mechanism: Binds all isoforms of VEGF-A; Fc region allows recycling via FcRn, increasing systemic half-life
• Dose: 1.25 mg in 0.05 mL (off-label for all ophthalmic uses)
• FDA approved for: Systemic colorectal cancer (Genentech/Roche) - ophthalmic use is entirely off-label
• Rationale for off-label use: Same parent antibody as ranibizumab; substantially cheaper (>90% cost reduction); CATT and IVAN trials proved non-inferiority to ranibizumab in AMD
• Intravitreal half-life: ~9.8 days
• Key consideration: Larger molecule; theoretical concern about systemic absorption via Fc-mediated transcytosis - higher systemic VEGF suppression than ranibizumab. Not used in pregnancy.
• Key trials: CATT, IVAN, VIBERA (Kanski's; Wills Eye Manual)

Aflibercept (Eylea) - 2 mg

• Class: Recombinant fusion protein (VEGF Trap)
• Structure: Extracellular domains of VEGFR-1 (domain 2) and VEGFR-2 (domain 3) fused to human IgG1 Fc
• Binding targets: VEGF-A (ALL isoforms), VEGF-B, and PlGF - broader than ranibizumab/bevacizumab
• Dose: 2 mg in 0.05 mL
• Binding affinity: Higher affinity for VEGF-A165 than ranibizumab (~100x higher)
• Intravitreal half-life: ~9 days
• FDA approvals: Neovascular AMD, DME, macular edema following CRVO/BRVO, diabetic retinopathy, ROP
• Dosing advantage: Standard regimen - 3 monthly loading doses, then every 8 weeks (q8w) - reducing injection frequency vs. monthly ranibizumab
• Key trials: VIEW 1, VIEW 2 (AMD); VIVID/VISTA (DME); COPERNICUS (CRVO); GALILEO (BRVO) (Kanski's; Wills Eye Manual)

Aflibercept 8 mg (Eylea HD) - HIGH DOSE

• Approved: 2023 (FDA) for neovascular AMD and DME
• Rationale: Higher molar dose increases duration of VEGF suppression, enabling q12-16 week intervals
• Key trial: PULSAR (nAMD) - 96-week results (2025) showed q12-16w dosing non-inferior to aflibercept 2 mg q8w; PHOTON (DME) - showed q12-16w intervals achievable in ~80% of patients
• Real-world data (2025): IRIS Registry data showed early use allows 12-week intervals in AMD and DME cohorts; median treatment interval extended from 6 weeks to 9.7 weeks in patients switched from aflibercept 2 mg

Brolucizumab (Beovu)

• Class: Humanized single-chain antibody fragment (scFv) - smallest anti-VEGF construct
• Molecular weight: ~26 kDa (smallest of the current agents)
• Mechanism: Binds all isoforms of VEGF-A; smallest size allows highest molar dose per injection volume
• Dose: 6 mg in 0.05 mL
• FDA approvals: Neovascular AMD (2019), DME (2022)
• Dosing advantage: After 3 monthly loading doses, q12w maintenance with possible q8w adjustment; potential for q16w in some patients
• Key safety concern: Higher rate of intraocular inflammation (IOI), including retinal vasculitis and occlusive vasculitis (~4.8% vs 1.1% for aflibercept in HAWK/HARRIER) - this limits its use
• Key trials: HAWK and HARRIER (AMD - showed non-inferiority to aflibercept q8w) (Wills Eye Manual)

Faricimab (Vabysmo) - BISPECIFIC

• Class: Bispecific antibody - inhibits TWO targets simultaneously
• Targets: VEGF-A + Angiopoietin-2 (Ang-2)
• Molecular weight: ~150 kDa
• Rationale for dual blockade: Ang-2 destabilizes retinal vasculature and synergizes with VEGF in driving neovascularization and permeability; blocking both pathways achieves better vascular stabilization
• Dose: 6 mg in 0.05 mL
• FDA approvals: Neovascular AMD (2022), DME (2022) - first new mechanism approved in >10 years
• Dosing advantage: Individualized TAE up to q16w intervals
• Key trials: TENAYA and LUCERNE (nAMD); YOSEMITE and RHINE (DME) - see Clinical Trials section
• 2024 2-year data (PMID 38382813): Sustained efficacy with ~45% of nAMD patients achieving q16w intervals; YOSEMITE/RHINE 2-year DME data (PMID 38158159) showed sustained VA gains with 52-56% at q12-16w intervals

Pegaptanib (Macugen)

• Class: RNA aptamer (not an antibody)
• Mechanism: Selectively binds VEGF-A165 isoform only (not other isoforms)
• Status: First FDA-approved anti-VEGF for AMD (2004), now largely obsolete - inferior efficacy vs. non-selective agents; limited selectivity is a disadvantage
• Dose: 0.3 mg q6w intravitreal

---

3. CLINICAL APPLICATIONS BY DISEASE

3.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

• Type 1 (occult): Below RPE
• Type 2 (classic): Above RPE, into subretinal space
• Type 3 (RAP - Retinal Angiomatous Proliferation): Intraretinal origin

• 3 monthly loading injections of any approved agent
• Then either: monthly PRN, fixed dosing (q8w aflibercept), or treat-and-extend (TAE)
• TAE is now the preferred approach in most centers: extend interval by 2 weeks when stable, reduce by 2 weeks when active disease recurs

3.2 Diabetic Macular Edema (DME)

• DRCR.net Protocol I: Intravitreal ranibizumab more effectively improves VA than focal/grid laser for center-involved DMO. Laser should be deferred 6 months after starting anti-VEGF. Good outcomes persist for at least 5 years.
• DRCR.net Protocol T: At 5 years, no significant difference in VA outcomes between aflibercept, bevacizumab, or ranibizumab. At 1 year, aflibercept was superior in patients with baseline VA 20/50 or worse.
• Patients with suboptimal response: add intravitreal corticosteroids (dexamethasone implant, fluocinolone acetonide implant). (Kanski's, p.530; Wills Eye Manual)

3.3 Retinal Vein Occlusion (RVO)

• Anti-VEGF for macular edema: treatment generally indicated when VA < 6/9 and/or central macular thickness >250 µm on OCT
• CRUISE study: Monthly ranibizumab for 6 months more effective than placebo
• COPERNICUS study: Intravitreal aflibercept effective even on as-needed protocol
• Bevacizumab also used off-label
• Adjunctive anti-VEGF (q6 weekly) for neovascularization (NVI, NVE), combined with PRP (Kanski's, p.547)

• FDA-approved: ranibizumab 0.5 mg, aflibercept 2 mg
• BRAVO study (ranibizumab): Mean VA gain of 18.3 letters at 6 months
• VIBRANT study (aflibercept): Superior to laser at 6 months
• GALILEO study (aflibercept, CRVO): Significant VA improvement

3.4 Proliferative Diabetic Retinopathy (PDR)

• Anti-VEGF (any agent) is an alternative to panretinal photocoagulation (PRP) and preferred as initial therapy when:
  • Concurrent DME is present (anti-VEGF addresses both)
  • Vitreous hemorrhage limits peripheral retina view
• DRCR.net Protocol S: Anti-VEGF (ranibizumab) non-inferior to PRP for PDR at 5 years, with better preservation of peripheral visual field and lower rates of DME
• Caution: Anti-VEGF alone without PRP requires reliable follow-up - patients lost to follow-up have worse outcomes (Wills Eye Manual)
• Pre-operative intravitreal bevacizumab reduces intraoperative hemorrhage and fibrovascular traction before vitrectomy

3.5 Retinopathy of Prematurity (ROP)

• VEGF is critical for normal retinal vascularization; premature birth causes relative hyperoxia, suppressing VEGF, halting vascularization, then hypoxia in avascular zones triggers pathological neovascularization
• Bevacizumab, ranibizumab, and aflibercept are used for Type 1 ROP (zone I, zone II posterior) and aggressive posterior ROP (AP-ROP)
• BEAT-ROP trial (2011): Bevacizumab monotherapy superior to laser for zone I, stage 3+ ROP
• CARE-ROP (2019) & Rainbow trial (2019): Ranibizumab vs. laser; lower-dose ranibizumab (0.1 mg) showed good efficacy with potentially less systemic VEGF suppression
• 2024 Network Meta-Analysis (PMID 38432359): Compared aflibercept, bevacizumab, conbercept, ranibizumab vs. laser - all anti-VEGF agents superior to laser for zone I disease. Ranibizumab at lower dose had favorable systemic safety profile.
• Key concern: Systemic absorption of intravitreal anti-VEGF in premature neonates - VEGF is critical for lung, brain, and kidney development. Ranibizumab (no Fc, faster systemic clearance) may be preferred over bevacizumab to minimize systemic suppression.
• Late recurrence: Anti-VEGF does not ablate avascular retina - recurrence at 1+ year is a known risk; long-term follow-up mandatory.

3.6 Myopic CNV (Pathological Myopia)

• Anti-VEGF is first-line treatment for CNV complicating pathological myopia (replaces PDT)
• RADIANCE trial: Ranibizumab superior to PDT; regimen guided by disease activity (VA stability)
• Single intravitreal injection often sufficient for a subset of patients; lower injection burden than AMD

3.7 Other Indications

• Iris/angle neovascularization (neovascular glaucoma): Adjunctive anti-VEGF prior to/with PRP to rapidly regress neovessels before surgery
• Central serous chorioretinopathy (CSR): Limited role; chronic CSR may respond to reduced-intensity PDT; anti-VEGF has modest benefit
• Choroidal hemangioma, retinal hemangioblastoma: Adjunctive use
• Corneal neovascularization: Topical and/or subconjunctival bevacizumab (off-label)
• Pterygium: Subconjunctival bevacizumab to reduce vascularity pre-excision

---

4. INTRAVITREAL INJECTION - SAFETY PROFILE

4.1 Common Procedure-Related Risks

4.2 Systemic Safety

• All agents may cause mild systemic VEGF suppression
• Meta-analyses show no significant increase in arterial thromboembolic events (ATEC) with anti-VEGF intravitreal treatment overall
• Kanski's specifically states: "Anti-VEGF treatment is not associated with arterial or venous thromboembolic events" (Kanski's, p.612)
• Bevacizumab causes more systemic VEGF suppression than ranibizumab (full antibody + Fc recycling) - theoretical concern; not conclusively shown to matter clinically except in cardiovascular-compromised patients
• Special populations: Avoid in pregnancy; use triamcinolone instead for pregnant patients with DMO

---

5. DOSING REGIMENS

5.1 Monthly (Fixed Interval)

• Maximizes VA gain in major trials
• Highest injection burden; not practical for long-term management
• Standard in MARINA, ANCHOR, VIVID/VISTA

5.2 PRN (Pro Re Nata / As-Needed)

• 3 loading monthly injections, then monthly monitoring; re-inject when recurrence criteria met
• Fewer injections but requires monthly clinic visits
• Real-world outcomes often inferior to monthly due to monitoring gaps

5.3 Treat-and-Extend (TAE)

• 3 loading doses, then extend interval by 2 weeks when inactive, reduce by 2 weeks when active
• Maximum interval varies by agent: 16 weeks (faricimab, brolucizumab, aflibercept 8 mg), 12 weeks (ranibizumab, bevacizumab, aflibercept 2 mg) in most protocols
• Reduces injection burden while maintaining efficacy; now the preferred regimen in most high-volume centers

---

6. LANDMARK CLINICAL TRIALS

6.1 Age-Related Macular Degeneration

6.2 Diabetic Macular Edema

6.3 Retinal Vein Occlusion

6.4 PDR

6.5 ROP

---

7. RESISTANCE AND SUBOPTIMAL RESPONSE

• Switching agents: Evidence supports switching from one agent to another (e.g., bevacizumab to ranibizumab, or to aflibercept) when response wanes. Faricimab is an option for refractory cases due to its dual mechanism.
• 2025 consensus recommendations (PMID 39824523): Switching to faricimab from current anti-VEGF - evidence-based indications include frequent reinjection requirements, persistent fluid, or anti-VEGF fatigue.
• Adjunctive therapy: Intravitreal dexamethasone implant (Ozurdex) or fluocinolone acetonide implant (Iluvien) for refractory DME
• COMRADE study: Ranibizumab showed significantly better VA than dexamethasone implant at 6 months for RVO-related ME

---

8. RECENT ADVANCES (2023-2026)

8.1 Faricimab - Bispecific Antibody Era

• Non-inferiority to aflibercept with extended intervals up to q16w
• ~45% of nAMD patients and ~52-56% of DME patients achieving q12-16w dosing intervals
• Network meta-analysis 2025 (PMID 40241463) confirms faricimab and high-dose aflibercept as efficacy leaders for nAMD

8.2 High-Dose Aflibercept (Eylea HD) 8 mg

• FDA-approved 2023 (nAMD, DME)
• PULSAR 96-week results (2025): q12-16w dosing non-inferior to standard aflibercept q8w
• Real-world data: switching from aflibercept 2 mg to 8 mg extended median interval from 6 to 9.7 weeks; switching from faricimab to 8 mg was less effective at extension (median 6 to 8.1 weeks), suggesting faricimab's dual mechanism confers additional benefit in refractory cases
• PHOTON: DME patients on q12-16w intervals (~80% achieved extended dosing)

8.3 Port Delivery System (PDS)

• Concept: Surgically implanted refillable reservoir in the sclera that provides continuous sustained release of ranibizumab
• ARCHWAY trial (Phase 3, nAMD): PDS with ranibizumab 100 mg/mL refilled q24w non-inferior to monthly IVI ranibizumab
• Pagoda RCT (2025, PMID 40048197, JAMA Ophthalmol): Phase 3 trial showing PDS ranibizumab equivalent to monthly ranibizumab for DME - major step toward injection-free management
• Limitation: Requires a surgical procedure for implantation and periodic refill; complications include vitreous hemorrhage, conjunctival bleb, and device-related events

8.4 Gene Therapy - The Next Frontier

• AAV8 vector carrying a gene encoding a ranibizumab-like anti-VEGF Fab fragment
• Delivery: subretinal (surgical) or suprachoroidal (in-office SCS Microinjector)
• Phase 1/2a (Lancet 2024, PMID 38554726): dose-escalation, subretinal - durable reductions in injection burden
• Phase 2 LUNA (2025): 2-year results - ~89-90% reduction in annualized anti-VEGF injections (from ~10/year to 0.9-1.1); 46-61% of participants received ≤1 total injection cumulatively
• Phase 3 ATMOSPHERE and ASCENT trials: topline data expected 2026-2027
• Suprachoroidal delivery Phase 3 for DR being planned

• AAV2 intravitreal vector
• LUNA trial (Phase 2): 94% reduction in injection burden
• Acquired by Eli Lilly - signals major commercial confidence

• Intravitreal AAV; encodes both anti-VEGF Fab and anti-PDGF-B DARPin
• Phase 2: 80% reduction in injection burden; potential for once-only treatment

8.5 Anti-VEGF Biosimilars

8.6 OPT-302 (Anti-VEGF-C/D - Tyrosine Kinase Inhibitor Adjunct)

• OPT-302 is a soluble form of VEGFR-3 that traps VEGF-C and VEGF-D (not targeted by current anti-VEGF agents)
• Phase 2b: Combination with ranibizumab superior to ranibizumab monotherapy in nAMD
• Rationale: VEGF-C/D may contribute to persistent fluid despite VEGF-A blockade

8.7 Emerging Delivery Systems

• Suprachoroidal injection: CLS-AX (axitinib - tyrosine kinase inhibitor) delivered suprachoroidally in Phase 3 trials - 6-month duration possible
• Sustained-release intravitreal implants: GB-102 (sunitinib malate intravitreal depot), KSI-301 (anti-VEGF antibody biopolymer conjugate) - early clinical trials
• Topical anti-VEGF: Currently limited by poor bioavailability; research ongoing (OCS-01 dexamethasone/bevacizumab eye drops)

8.8 OCT Biomarkers Predicting Anti-VEGF Response

• Predictors of good response: Presence of SRF, intact ellipsoid zone, disorganization of retinal inner layers (DRIL) absent
• Predictors of poor response: DRIL, outer nuclear layer thinning, hyperreflective foci, disrupted external limiting membrane

---

9. ANTI-VEGF IN OPHTHALMOLOGY - SUMMARY ALGORITHM

Presenting condition
│
├── nAMD (active MNV)
│   └── First-line: Faricimab or Aflibercept 8 mg (TAE up to q16w)
│       OR Aflibercept 2 mg / Ranibizumab / Bevacizumab (off-label)
│
├── Diabetic Macular Edema (center-involving)
│   └── First-line: Faricimab / Aflibercept 8 mg / Aflibercept 2 mg / Ranibizumab
│       Add steroid implant if inadequate response
│
├── PDR (without clear view / + DME)
│   └── Anti-VEGF ± PRP; preoperative anti-VEGF before vitrectomy
│
├── RVO (CRVO/BRVO) - macular edema
│   └── Ranibizumab or Aflibercept (FDA-approved); Bevacizumab off-label
│
├── ROP (Type 1 / AP-ROP)
│   └── Anti-VEGF preferred for zone I; laser for zone II/III; ranibizumab lower systemic risk
│
└── Myopic CNV
    └── Anti-VEGF first-line (PRN); single injection often sufficient

---

10. KEY POINTS FOR CLINICAL PRACTICE

1. Treatment should start within 2-3 weeks of symptom onset in active MNV - delay worsens prognosis
2. Better baseline VA = better final VA regardless of agent used
3. Genetic factors (CFH, ARMS2/HTRA1 polymorphisms) influence treatment response in AMD
4. TAE is the dominant regimen in modern practice - reduces injection burden without sacrificing efficacy
5. Faricimab and high-dose aflibercept are now the preferred first-line agents where access permits, offering the longest treatment intervals
6. Brolucizumab caution: Reserve for experienced centers; higher IOI/vasculitis risk
7. Pregnancy: Avoid anti-VEGF; use triamcinolone for DMO if needed
8. ROP: Mandatory long-term follow-up after anti-VEGF - late recurrence at >1 year is known
9. Gene therapy (2026-2027): Pivotal Phase 3 data expected - may fundamentally change nAMD management within the next 2-5 years
10. Biosimilars are expanding global access; clinically equivalent to originators in completed Phase 3 trials

---

• Kanski's Clinical Ophthalmology: A Systematic Approach, 10th ed. (Primary reference throughout)
• The Wills Eye Manual, 8th ed.
• Goodman & Gilman's The Pharmacological Basis of Therapeutics
• TENAYA/LUCERNE 2-year results: Ophthalmology 2024 (PMID 38382813)
• YOSEMITE/RHINE 2-year DME results: Ophthalmology 2024 (PMID 38158159)
• RGX-314 gene therapy Phase 1/2a: Lancet 2024 (PMID 38554726)
• ROP network meta-analysis: Surv Ophthalmol 2024 (PMID 38432359)
• Pagoda RCT (PDS for DME): JAMA Ophthalmol 2025 (PMID 40048197)
• Biosimilars Cochrane review: Cochrane 2024 (PMID 38829176)
• Anti-VEGF for PDR meta-analysis: Ophthalmol Retina 2025 (PMID 39128789)
• Comparative nAMD network meta-analysis 2025: Acta Ophthalmol 2025 (PMID 40241463)
• OCT biomarkers DME: Ophthalmology 2026 (PMID 40803536)
• Gene therapy pipeline review: retina-specialist.com (June 2026)

---

1. Click, don't right-click - Left-click the link directly. Right-clicking and "Save As" may not work for sandbox paths.
2. Browser blocking - Some browsers block file downloads from unfamiliar sources. Check for a download notification bar at the top/bottom of your browser window and allow it.
3. Pop-up blocker - If your browser has a pop-up blocker active, it may intercept the download. Temporarily disable it and try again.
4. Interface limitation - If you are using this tool through an API or embedded interface, file downloads via sandbox paths may not be supported in your specific client. In that case, let me know and I can:
   • Convert the file to a base64 string you can decode locally
   • Provide the full JavaScript source so you can run it locally with node create_ppt.js (requires npm install pptxgenjs)

1. Direct link (click, don't right-click):

   Anti VEGF Ophthalmology

   Presentation · PPTX

   Download
2. Run locally - If you have Node.js installed, save the script and run it yourself:

   npm install pptxgenjs
   node create_ppt.js
   

   The script is at /home/daytona/workspace/antivegf-ppt/create_ppt.js - I can paste it here in full if needed.
3. Convert to base64 - I can output the file as a base64 string that you can decode on your machine with a single command.

---

Slide 1 — Title

• Anti-VEGF Therapy in Ophthalmology
• Basic Science • Pharmacology • Clinical Applications • Recent Advances
• VEGF Family | Agents | Landmark Trials | Gene Therapy 2026
• Sources: Kanski's 10e • Wills Eye Manual • PubMed 2024-2026

---

Slide 2 — VEGF Biology

• VEGF Family Members: VEGF-A (primary driver), VEGF-B (accessory), VEGF-C/D (lymphangiogenesis, targeted by OPT-302), PlGF (amplifies VEGF-A); key isoforms: 121, 165, 189
• Receptors: VEGFR-1 (decoy), VEGFR-2 (main signaling — proliferation + permeability), VEGFR-3 (lymphatic)
• Downstream VEGFR-2 Signaling: PI3K/Akt, MAPK/ERK, tight junction disruption (ZO-1, occludin), HIF-1α is upstream master switch

---

Slide 3 — Schematic (Pathway Diagram)

• Pathology cascade: Ischemia/Hypoxia → HIF-1α Activation → VEGF-A Upregulation → VEGFR-2 Activation → Neovascularization & Vascular Leakage
• Ang-2 arm: Ang-2 Release → Tie-2 Destabilization (synergizes with VEGF)
• Anti-VEGF agents shown blocking pathway: Ranibizumab (Fab), Bevacizumab (IgG1), Aflibercept (Fusion protein), Faricimab (Bispecific — also blocks Ang-2), Brolucizumab (scFv)

---

Slide 4 — Agents At a Glance (Table)

---

Slide 5 — Intravitreal Injection Technique & Safety

• Technique: Povidone-iodine 5% (min 3 min), topical ± subconjunctival lidocaine, 3.5-4.0 mm from limbus (phakic), inferotemporal/superotemporal quadrant, bilateral at separate sessions
• Safety: Endophthalmitis ~0.5-1%, RPE tear (continue Rx), IOI 0.1-0.3% (brolucizumab ~4.8%), IOP elevation, systemic ATEC NOT significantly increased

---

Slide 6 — Clinical Applications (4-box layout)

• nAMD: All MNV subtypes respond; treat within 2-3 weeks; TAE up to q16w; MARINA, ANCHOR, VIEW 1/2
• DME: First-line for centre-involving DME; aflibercept superior at 1yr if VA ≤20/50; all equal at 5yr; add steroid if suboptimal
• RVO: CRVO/BRVO — ranibizumab or aflibercept; CRUISE +14.9 letters; BRAVO +18.3 letters; adjunctive for NVI
• PDR/ROP/Other: Protocol S non-inferior to PRP; preoperative anti-VEGF; ROP Type 1; myopic CNV single injection often sufficient

---

Slide 7 — Dosing Regimens (3-column layout)

• Fixed Monthly: 3 loading + monthly; max VA gain; 12 injections/year; now rarely used long-term
• PRN: 3 loading, monthly monitoring, re-inject on recurrence; real-world outcomes often inferior
• Treat-and-Extend (TAE): Preferred today; extend 2 wks when inactive, reduce when fluid recurs; max q16w (faricimab/HD-AFL)

---

Slide 8 — Landmark Trials: nAMD (Table)

---

Slide 9 — Landmark Trials: DME, RVO & PDR (Table)

---

Slide 10 — Treatment Flowchart

• Presenting Retinal Condition
• → Active Exudation on OCT? No → Observe / Optimise Systemic
• → Yes → 3 Monthly Loading Injections (any approved agent)
• → Assess Response at Month 3
  • Good → Treat-and-Extend (TAE, max q16w) → Extend interval 2 wks each visit
  • Poor/Partial → Switch Agent or Add Steroid → Faricimab / HD-Aflibercept 8mg
• Footer: Faricimab q16w max | Aflibercept 8mg q12-16w | Ranibizumab/Bevacizumab q8-12w max TAE

---

Slide 11 — Resistance & Switching

• Recognising suboptimal response: Persistent SRF/IRF ≥3 injections, failure to extend (tachyphylaxis), declining VA, mechanisms (anti-drug antibodies, VEGF-C/D escape, fibrosis)
• Management: Switch agent, upgrade to faricimab (+ Ang-2 block), upgrade to AFL 8mg, add steroid implant
• Evidence 2025: AFL 2mg → 8mg: interval 6→9.7 wks (70% ≥8w); faricimab → AFL 8mg: only 54% ≥8w; COMRADE: ranibizumab > dexamethasone for RVO-ME

---

Slide 12 — Recent Advances 2023-2026

1. Faricimab (Vabysmo): First dual VEGF/Ang-2 agent; 45% on q16w at 2 years
2. Aflibercept 8mg (Eylea HD, 2023): PULSAR q12-16w non-inferior; PHOTON 80% on extended dosing
3. Port Delivery System (PDS): ARCHWAY q24w = monthly IVI; Pagoda RCT 2025 equivalent for DME
4. Biosimilars (Cochrane 2024): SB11, ABP 938 clinically equivalent to originators
5. OPT-302 (VEGF-C/D): Phase 2b superior to ranibizumab monotherapy for nAMD
6. OCT Biomarkers 2026: DRIL, ellipsoid zone integrity predict DME response

---

Slide 13 — Gene Therapy Pipeline (3-card layout)

• Concept: Single administration converting retinal cells into anti-VEGF biofactories; all require corticosteroid prophylaxis
• ABBV-RGX-314 (RegenxBio/AbbVie): AAV8, subretinal/suprachoroidal; LUNA Phase 2: 89-90% injection reduction; Phase 3 data H2 2026-2027
• Ixoberogene (Adverum/Eli Lilly): AAV2 intravitreal; 94% injection reduction; acquired by Eli Lilly
• 4D-150 (4D Molecular): Intravitreal AAV; anti-VEGF + anti-PDGF-B; 80% reduction; once-only potential

---

Slide 14 — Anti-VEGF in ROP

• Pathophysiology: Premature birth → hyperoxia → VEGF suppressed → vascularisation halts → hypoxia → VEGF surge → neovascularization; preferred for Zone I / posterior Zone II
• Trials: BEAT-ROP 2011 (bevacizumab > laser, Zone I); CARE-ROP/Rainbow 2019 (ranibizumab superior; 0.1mg preferred); NMA 2024: all anti-VEGF > laser for Zone I
• Cautions: Systemic VEGF suppression in neonates; ranibizumab (no Fc) preferred; late recurrence >1 year — long-term follow-up mandatory

---

Slide 15 — Clinical Pearls

1. Start within 2-3 weeks of symptom onset for active MNV
2. Better baseline VA = better final VA; CFH, ARMS2/HTRA1 genetics affect response
3. TAE is now the dominant regimen
4. Faricimab or HD-aflibercept preferred first-line (longest intervals)
5. Brolucizumab: reserve for experienced centres; ~4.8% vasculitis risk
6. Pregnancy: avoid anti-VEGF; use intravitreal triamcinolone

• Future 2026+: Phase 3 gene therapy data expected; biosimilars expanding access globally

---

Slide 16 — References

• Kanski's Clinical Ophthalmology 10e; Wills Eye Manual 8e; Goodman & Gilman
• TENAYA/LUCERNE: PMID 38382813 | YOSEMITE/RHINE: PMID 38158159
• RGX-314: PMID 38554726 | Biosimilars: PMID 38829176
• Pagoda RCT: PMID 40048197 | ROP NMA: PMID 38432359
• PDR meta-analysis: PMID 39128789 | OCT biomarkers: PMID 40803536
• Gene therapy pipeline: retina-specialist.com June 2026; AAO 2025

---

---

Anti-VEGF Therapy in Ophthalmology

Comprehensive Notes — Basic to Advanced, with Clinical Trials and Recent Advances (2026)

---

PART 1: FOUNDATIONS — UNDERSTANDING VEGF

1.1 What is VEGF?

1.2 The VEGF Family

• VEGF-A165 (165 amino acids): The most abundant and biologically potent isoform; binds both VEGFR-1 and VEGFR-2 and heparan sulfate proteoglycans in the extracellular matrix (ECM). This is the primary therapeutic target.
• VEGF-A121: Freely diffusible (does not bind ECM); less potent.
• VEGF-A189: Tightly ECM-bound; least diffusible.
• VEGF-A110: Proteolytic cleavage product of VEGF-A165; also active.

1.3 VEGF Receptors — Structure and Signaling

• High affinity for VEGF-A, VEGF-B, and PlGF
• Paradoxically, largely acts as a decoy receptor or negative regulator in normal vessels — sequesters VEGF-A away from VEGFR-2, modulating signaling intensity
• A soluble form (sFlt-1, lacking the transmembrane domain) is naturally secreted and acts as an endogenous anti-VEGF mechanism
• In the retina, sFlt-1 from vascular endothelium creates a physiological VEGF gradient that guides normal vascularization

• The primary signaling receptor for VEGF-A-mediated angiogenesis and permeability
• Lower binding affinity for VEGF-A than VEGFR-1, but far higher signaling potency
• Upon VEGF-A binding, VEGFR-2 dimerizes and undergoes autophosphorylation at multiple tyrosine residues
• Downstream pathways activated:
  • PI3K → Akt → mTOR: endothelial cell survival, glucose uptake, protein synthesis
  • PLC-γ → DAG/IP3 → PKC: vascular permeability, tight junction disruption
  • RAS → RAF → MAPK/ERK: endothelial proliferation and migration
  • Src kinase: phosphorylation of VE-cadherin and claudin-5, opening of intercellular junctions → vascular leakage
  • FAK (focal adhesion kinase): cytoskeletal reorganization and endothelial migration

• Expressed predominantly on lymphatic endothelium
• Binds VEGF-C and VEGF-D
• Governs lymphangiogenesis; relevant in corneal neovascularization research

1.4 The Angiopoietin-Tie Axis (Critical for Understanding Faricimab)

• Angiopoietin-1 (Ang-1): Produced by pericytes; activates Tie2 on endothelial cells → promotes vascular stability, reduces permeability, anti-inflammatory
• Angiopoietin-2 (Ang-2): Stored in Weibel-Palade bodies of endothelial cells; acts as a competitive antagonist of Ang-1 at Tie2 — destabilizes blood vessels, sensitizing them to VEGF-driven sprouting and permeability
• Under pathological conditions (ischemia, inflammation, diabetic retinopathy, AMD), Ang-2 is upregulated and released, tipping the balance toward vascular instability
• VEGF-A and Ang-2 are synergistic: Ang-2 destabilizes the vessel wall, VEGF drives new sprouting. Blocking only VEGF-A leaves Ang-2-driven permeability unchecked — this is the rationale for faricimab's dual blockade.
• Ang-2 also promotes macrophage activation and inflammatory cytokine release, contributing to the chronic inflammatory component of neovascular AMD and DME.

1.5 VEGF in Normal Retinal Physiology

1. Retinal vascularization during development: The nasal retina is fully vascularized by 8 months of gestation; the temporal periphery by ~1 month after birth. VEGF is the primary driver of this centrifugal vascularization, guided by retinal astrocytes that create a spatial VEGF gradient ahead of advancing vessels. (Kanski's, p.556)
2. Choriocapillaris maintenance: Low-level constitutive VEGF secretion by the RPE is required to maintain the fenestrated choriocapillaris that nourishes the outer retina. Loss of this trophic VEGF is believed to contribute to geographic atrophy in AMD — a potential unintended consequence of long-term anti-VEGF therapy.
3. Neuroprotection: VEGF has direct neuroprotective effects on retinal ganglion cells and photoreceptors via VEGFR-2 signaling. This is relevant in ROP — excessive VEGF suppression may impair retinal neurodevelopment.
4. Iris and trabecular vasculature: Normal iris perfusion depends on basal VEGF. This is exploited when anti-VEGF agents rapidly regress iris neovessels (NVI) in neovascular glaucoma.

1.6 VEGF in Ocular Disease — The Hypoxia Cascade

Tissue hypoxia / ischemia / RPE stress
          ↓
Stabilization of HIF-1α (Hypoxia Inducible Factor-1 alpha)
          ↓
HIF-1α translocates to nucleus → binds HREs (Hypoxia Response Elements)
          ↓
Transcriptional upregulation of VEGF-A gene
          ↓
VEGF-A secretion into the extracellular space
          ↓
VEGF-A binds VEGFR-2 on retinal/choroidal endothelial cells
          ↓
Endothelial proliferation + tight junction disruption
          ↓
Pathological neovascularization + vascular leakage
          ↓
Subretinal fluid (SRF) / intraretinal fluid (IRF) / hard exudates
          ↓
Photoreceptor damage → visual loss

---

PART 2: ANTI-VEGF AGENTS — DETAILED PHARMACOLOGY

2.1 Overview and Rationale for Intravitreal Delivery

• Intraocular drug concentrations in the micromolar range (orders of magnitude above the VEGF IC50)
• Minimal systemic exposure compared to IV administration
• Bypassing the blood-retinal barrier (BRB) entirely

• Anteriorly: aqueous humor drainage through the trabecular meshwork
• Across the BRB into systemic circulation — the rate depends heavily on molecular weight and the presence/absence of an Fc region (see pharmacokinetics below)

2.2 Pharmacokinetic Principles — Why Molecular Structure Matters

• Large molecules; slow diffusion through vitreous
• Fc region is recycled by neonatal Fc receptor (FcRn) in endothelial cells — this prolongs both intravitreal and systemic half-life
• FcRn-mediated transport across the blood-retinal barrier contributes to systemic absorption, raising systemic VEGF suppression

• Smaller; faster diffusion through vitreous
• No Fc region — not recycled by FcRn; cleared rapidly by proteolysis and renal filtration
• Shorter systemic half-life (~2 hours vs. weeks for full IgG) — preferred in pregnancy concerns and ROP (neonates)
• Intravitreal half-life ~9 days — similar to bevacizumab despite size difference (vitreous provides a protected depot)

• Fc region present (from IgG1) — some FcRn recycling
• Higher binding affinity for VEGF-A165 than ranibizumab (~100-fold) due to dual receptor domain architecture
• Intravitreal half-life ~9-10 days

• Smallest anti-VEGF agent; highest molar dose achievable in 0.05 mL
• No Fc; cleared systemically like a Fab
• Very high binding affinity; lowest frequency of dosing theoretically possible
• But: scFv architecture leaves the CDR3 loop exposed → risk of immune recognition → higher intraocular inflammation rate

2.3 Pegaptanib (Macugen) — Historical Context

2.4 Ranibizumab (Lucentis) — The Prototype Agent

• Improve retinal penetration (smaller molecule)
• Minimize systemic exposure (no Fc, no FcRn recycling)
• Reduce risk of systemic VEGF suppression

• Light chain + VH-CH1 heavy chain fragment
• Humanized (>95% human sequence) to minimize immunogenicity
• Binds all VEGF-A isoforms with high affinity (Kd ~46 pM for VEGF-A165)

1. Monthly (fixed): Used in major trials; ~95% maintain vision; 33-40% gain ≥3 lines. Monthly injections mean 12 per year — significant burden.
2. PRN (as-needed): 3 loading monthly injections; then monthly monitoring with re-injection on recurrence (defined as VA loss ≥5 ETDRS letters or OCT thickness increase ≥100 µm). Fewer injections but requires monthly clinic visits; real-world outcomes often inferior to fixed monthly.
3. Treat-and-Extend (TAE): 3 monthly loading injections; then extend interval by 2-week increments when disease is inactive; reduce by 2 weeks when activity recurs. Patient-specific maximum interval determined empirically (typically 8-12 weeks for ranibizumab). This is now the preferred strategy in most centres. (Kanski's, p.614)

2.5 Bevacizumab (Avastin) — The Off-Label Workhorse

• Same complementarity-determining regions (CDRs) as ranibizumab — identical VEGF-binding specificity
• Binds all VEGF-A isoforms with similar affinity
• The Fc region provides additional binding avidity through bivalent (two-armed) VEGF capture
• Clinical evidence (CATT, IVAN) demonstrates non-inferiority to ranibizumab

• Cost: ~$60-70 per ophthalmic dose vs. ~$1,800-2,000 for ranibizumab. In resource-limited settings, bevacizumab is the only accessible anti-VEGF.
• Requires repackaging by compounding pharmacies (the commercial vials contain ~400mg/16mL; each ophthalmic dose is 1.25mg/0.05mL)
• Repackaging introduces sterility concerns — bacterial endophthalmitis clusters have been reported from contaminated compounded bevacizumab

• Full IgG1 with Fc → FcRn-mediated recycling → longer systemic half-life (~20 days)
• Measurably suppresses systemic plasma VEGF levels more than ranibizumab
• Some studies suggest marginally higher risk of serious systemic adverse events vs. ranibizumab (Kanski's), but CATT 2-year data showed no significant difference in overall serious adverse events
• Avoid in pregnancy: VEGF is essential for placental development; systemic bevacizumab (FDA approved for cancer) causes fetal harm. For intravitreal use, systemic absorption is low, but risk is non-zero — use triamcinolone instead in pregnant patients with DMO.

2.6 Aflibercept 2 mg (Eylea) — The VEGF Trap

• The second Ig-like domain of VEGFR-1 (which binds VEGF-A and PlGF with very high affinity)
• The third Ig-like domain of VEGFR-2 (which binds VEGF-A and VEGF-B)
• Fused to the Fc domain of human IgG1 (provides FcRn-mediated half-life extension and bivalency)

• Trans-activating VEGFR-2 in a VEGFR-1-dependent manner
• Promoting macrophage recruitment and inflammatory angiogenesis Blocking PlGF (not achieved by ranibizumab/bevacizumab) may provide additional benefit in diabetic retinopathy and choroidal neovascularization.

• 3 monthly loading injections
• Then every 8 weeks (q8w) maintenance

2.7 Aflibercept 8 mg (Eylea HD) — Higher Dose, Longer Duration

• PULSAR (nAMD): aflibercept 8 mg at q12w or q16w vs. AFL 2 mg q8w — non-inferior at 48 weeks; 96-week results (Ophthalmology, published August 2025) confirmed sustained non-inferiority with the majority of patients maintaining extended dosing intervals.
• PHOTON (DME): ~80% of patients achieved q12-16w dosing by the end of the study.

2.8 Brolucizumab (Beovu) — Smallest Agent, Highest Molar Dose

• Mechanism: Hypothesized to relate to the scFv architecture — without an Fc domain, the drug's antigen-binding site (CDR loops) are more exposed, potentially triggering immune recognition; alternatively, aggregates may act as immune complexes.
• Clinical implications: Brolucizumab should be reserved for experienced retinal centres with the ability to manage IOI. Patients should be counselled about warning symptoms (pain, redness, floaters, vision change) requiring urgent review.

2.9 Faricimab (Vabysmo) — The Bispecific Revolution

1. VEGF-A — all isoforms, via a conventional anti-VEGF Fab arm
2. Angiopoietin-2 (Ang-2) — via a separate binding arm based on anti-Ang-2 VH domain

• Superior vascular stabilization vs. VEGF-A monotherapy alone
• Reduced inflammatory signaling (Ang-2 promotes macrophage activation)
• Potentially longer treatment intervals per injection

---

PART 3: INTRAVITREAL INJECTION — TECHNIQUE, CONTRAINDICATIONS, MONITORING

3.1 Setting and Preparation

1. Confirm the indication, the correct eye (marked), and that the appropriate drug and dose are available
2. Check recent anterior and posterior segment examination and IOP — exclude active infection or uncontrolled IOP
3. Explain procedure and risks; obtain informed consent
4. Instill topical anaesthetic (proxymetacaine or oxybuprocaine) and mydriatic drops
5. Apply 5% povidone-iodine to the ocular surface and conjunctival fornices — allow minimum 3 minutes contact time before injection (this is the most critical step for endophthalmitis prevention)
6. Subconjunctival lidocaine 1-2% may supplement topical anaesthesia
7. Place sterile drape; use a speculum to prevent lid contamination during injection
8. Mark injection site: 3.5-4.0 mm from the limbus (phakic eyes); 3.0 mm from limbus (pseudophakic or aphakic) — inferotemporal or superotemporal quadrant preferred
9. Insert needle (30G, 0.5 inch) perpendicular to the sclera, aimed toward the centre of the vitreous cavity (not the lens)
10. Inject slowly; withdraw needle
11. Check for perfusion of the central retinal artery (check for light perception at minimum)
12. Apply cotton-tip pressure to the injection site briefly

3.2 Contraindications

• Active periocular or intraocular infection
• Active severe intraocular inflammation (uveitis)
• Known hypersensitivity to the specific agent

• Uncontrolled IOP (>30 mmHg at time of injection)
• Recent intraocular surgery (within 4-6 weeks)
• Pregnancy (avoid anti-VEGF — use intravitreal triamcinolone instead)
• Active systemic infection
• Recent (within 3 months) stroke or myocardial infarction (systemic VEGF suppression concern — especially bevacizumab)
• Mature fibrotic disciform scar (no active VEGF-driven disease — treatment futile)

3.3 Safety Profile — Ocular Complications

• Rate approximately 0.5-1% per injection with standard aseptic technique (Kanski's)
• Most cases (>90%) are infectious — Staphylococcus epidermidis (from eyelid flora) is most common
• Sterile endophthalmitis (immune-mediated, no growth on culture) is less common but has been described with certain agents, particularly after bevacizumab from compounding pharmacies
• Presentation: pain, hypopyon, severe visual loss within 24-72 hours post-injection
• Management: vitreous tap and injection of intravitreal antibiotics (vancomycin + ceftazidime); vitrectomy if no improvement

• Rare (<0.1% per injection); typically rhegmatogenous from needle-related retinal break

• Occur in eyes with large, vascular pigment epithelial detachments (PEDs)
• Contraction of CNV following VEGF suppression can pull the RPE, causing a tear at the junction of the PED and attached RPE
• Does NOT constitute a reason to stop treatment (the tear has already occurred); treatment should continue to suppress the underlying CNV

• Rate: ~0.1-0.3% for ranibizumab/bevacizumab/aflibercept; ~4.8% for brolucizumab; ~1.5% for faricimab
• Brolucizumab-associated IOI can progress to retinal vasculitis and retinal artery occlusion — vision-threatening

• Transient post-injection IOP spike (minutes to hours): common and benign — due to increased vitreous volume
• Sustained IOP elevation: reported in a subset of eyes receiving long-term anti-VEGF therapy (possible trabecular meshwork damage from repeated injections or immune complexes); monitor IOP at each visit

• Rare; from inadvertent needle contact with the posterior lens capsule

3.4 Systemic Safety

• Arterial thromboembolic events (ATEC — stroke, MI): Kanski's states explicitly that "Anti-VEGF treatment is not associated with arterial or venous thromboembolic events." Meta-analyses confirm no significant increase in ATEC with intravitreal anti-VEGF overall, though the CATT study showed a non-significant trend toward more non-ocular hemorrhage with bevacizumab.
• Blood pressure elevation: Systemic bevacizumab (IV for cancer) causes significant hypertension; this is less of a concern with intravitreal doses but worth monitoring in at-risk patients
• Cardiovascular risk in the elderly: Population-based studies have not demonstrated a clinically meaningful increase in cardiovascular mortality with intravitreal anti-VEGF
• Differential systemic suppression:
  • Ranibizumab (Fab, no Fc): minimal systemic VEGF suppression (~renal clearance in hours)
  • Bevacizumab (full IgG1, Fc): moderate systemic suppression (FcRn recycling, weeks of circulatory half-life)
  • This pharmacokinetic difference is particularly relevant in ROP (premature neonates) and pregnancy, where systemic VEGF suppression carries developmental risk

---

PART 4: CLINICAL APPLICATIONS — DISEASE BY DISEASE

4.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

Pathophysiology in Depth

1. Early AMD: Drusen (deposits of extracellular material including complement components, lipids, and vitronectin) accumulate beneath the RPE; focal RPE dysfunction begins
2. Complement activation: Variants in complement factor H (CFH), complement factor B (CFB), complement factor I (CFI), and C3 are strongly associated with AMD. Complement activation products (C3a, C5a) promote RPE stress and inflammation
3. RPE stress → VEGF upregulation: Oxidative stress, mitochondrial dysfunction, complement attack, and AGE accumulation in Bruch's membrane all contribute to RPE VEGF secretion
4. VEGF-A action: Binds endothelial cell VEGFR-2 in the choriocapillaris → promotes endothelial sprouting through Bruch's membrane breaches → formation of Macular Neovascularization (MNV)
5. PEDF/CFH imbalance: The inhibitory mediators PEDF (Pigment Epithelium-Derived Factor) and CFH are simultaneously downregulated, removing the brakes on neovascularization (Kanski's, p.607)
6. Neovascular membrane types:
   • Type 1 MNV (occult/classic occult): beneath the RPE — less exudative acutely; more chronic
   • Type 2 MNV (classic): above the RPE, in the subretinal space — highly exudative, rapid visual loss
   • Type 3 MNV (RAP — Retinal Angiomatous Proliferation): arises intraretinally, grows downward; associated with large PEDs; responds to anti-VEGF but recurs frequently
7. End-stage: Fibrotic disciform scar (no viable photoreceptors over the scar; anti-VEGF has no benefit at this stage)

Treatment Principles

• Inhibitors of VEGF block its interaction with receptors on the endothelial cell surface and retard or reverse vessel growth. (Kanski's, p.612)
• Treatment must start within 2-3 weeks of symptom onset — delay allows progressive photoreceptor damage that cannot be reversed
• Active disease criteria (treat): Presence of SRF, IRF, retinal haemorrhage, FA leakage, enlarging MNV on OCT-A, or deteriorating VA attributable to MNV activity
• Contraindication: Mature fibrotic disciform scar — no active VEGF-driven disease
• Genetic factors (CFH, ARMS2/HTRA1 polymorphisms) contribute to variability in treatment response between patients
• TIP from Kanski's: "In patients with AMD secondary to MNV, the better the visual acuity at the onset of anti-VEGF treatment, the better the final visual acuity."
• Note: younger age at treatment onset may paradoxically confer worse outcome (possibly because CNV is more aggressive in younger patients)

Dosing and Monitoring

• Loading phase: 3 monthly injections (all agents)
• Maintenance: TAE extending by 2-week increments when stable (no SRF/IRF on OCT); reducing by 2 weeks on recurrence
• Maximum intervals by agent:
  • Ranibizumab / bevacizumab: typically q8-12w maximum
  • Aflibercept 2mg: q8-12w (VIEW studies support q8w)
  • Aflibercept 8mg: q12-16w (PULSAR)
  • Brolucizumab: q12w standard, q8w if active (HAWK/HARRIER)
  • Faricimab: q12-16w (TENAYA/LUCERNE; 60% on q16w in trials per Kanski's)

• Refractory cases combined with anti-VEGF (combination therapy)
• Polypoidal choroidal vasculopathy (PCV) — PDT ± anti-VEGF
• Central serous chorioretinopathy (reduced-intensity PDT)
• Patients who refuse intravitreal injections (Kanski's, p.615)

4.2 Diabetic Macular Edema (DME)

Pathophysiology

1. Pericyte loss: Pericytes support capillary integrity; in diabetes, advanced glycation end-products (AGEs) and polyol pathway activation cause pericyte apoptosis — capillaries lose structural support and become leaky
2. Tight junction disruption: VEGF-A (upregulated by Müller cells and retinal pericytes in response to hyperglycemia-driven ischemia) activates Src kinase in endothelial cells → phosphorylation of occludin and ZO-1 (tight junction proteins) → intercellular gap formation → fluid extravasation
3. Inflammatory mediators: TNF-α, IL-1β, ICAM-1 (leukostasis), and VEGF-A all contribute; anti-inflammatory agents (steroids) can supplement anti-VEGF when VEGF-A alone is insufficient
4. Müller cell dysfunction: Müller cells normally act as water channels (via AQP4 aquaporins) and maintain retinal homeostasis; in DME, Müller cell stress amplifies VEGF secretion and impairs fluid clearance
5. Result: Macular thickening with SRF, IRF, hard exudates; photoreceptor damage if left untreated

Treatment (Anti-VEGF as First Line)

• Extrafoveal microaneurysms causing significant edema (focal laser)
• Patients where anti-VEGF is contraindicated

• Dexamethasone implant (Ozurdex) 700 µg: biodegradable implant; effect ~2-3 months; risks include IOP elevation and cataract progression
• Fluocinolone acetonide implant (Iluvien) 190 µg: 3-year slow-release implant; appropriate for pseudophakic patients with chronic DME

4.3 Retinal Vein Occlusion (RVO)

Mechanism of Vision Loss in RVO

• Retinal venous hypertension and capillary hydrostatic pressure increase → fluid leaks into the macula → macular edema (ME)
• Retinal ischemia in areas of capillary non-perfusion → VEGF upregulation → Macular edema AND risk of retinal/iris neovascularization
• Iris neovascularization (NVI) occurs in ~20% of CRVO cases (mean 4 weeks post-onset) — can progress to neovascular glaucoma

4.4 Proliferative Diabetic Retinopathy (PDR)

• Better preservation of peripheral visual field (PRP destroys peripheral photoreceptors)
• Lower rates of DME development or worsening (PRP can worsen ME; ranibizumab actively treats it)
• Better outcomes in eyes with concurrent DME

• Concurrent center-involving DME (anti-VEGF addresses both conditions)
• Vitreous hemorrhage obscures peripheral retina view (cannot perform PRP)
• Patient unwilling or unable to undergo PRP (Wills Eye Manual)

• Reduces intraoperative bleeding (regression of fibrovascular NV)
• Decreases surgical difficulty (fibrovascular membranes become less vascular)
• Reduces risk of iatrogenic retinal breaks during membrane peeling
• Reduces rate of postoperative recurrent vitreous hemorrhage

4.5 Retinopathy of Prematurity (ROP)

Pathophysiology

• Phase 1 (hyperoxia phase): Premature birth exposes the retina to relatively higher oxygen tensions than the hypoxic uterine environment → VEGF expression is suppressed (oxygen shuts off HIF-1α) → normal vascularization arrests → an expanding avascular zone forms
• Phase 2 (hypoxia/proliferative phase): As the infant matures, metabolic demand of the unvascularized retina exceeds oxygen delivery → severe retinal hypoxia → massive HIF-1α activation → VEGF surge → pathological neovascularization at the junction of vascular and avascular retina → ridge formation, fibrovascular membranes, tractional retinal detachment (stages 1-5)

• Zone I / Zone II posterior / Zone III: location of disease (Zone I = posterior, worst prognosis)
• Stages 1-5: severity (1 = demarcation line; 2 = ridge; 3 = extraretinal fibrovascular proliferation; 4 = partial RD; 5 = total RD)
• Plus disease: vascular dilation and tortuosity (marker of severity, requires treatment regardless of stage)
• Aggressive Posterior ROP (AP-ROP): rapidly progressive, zone I/II posterior, plus disease, high-risk

• Bevacizumab dose typically used: 0.625 mg in 0.025 mL (half the adult ophthalmic dose)
• Ranibizumab dose: 0.1 mg or 0.2 mg (CARE-ROP)
• Aflibercept: 0.4 mg (used in some centres; FDA approved for ROP 2023)

• No Fc region → no FcRn recycling → faster systemic clearance (hours rather than weeks)
• Measurably less systemic VEGF suppression in pharmacokinetic studies
• VEGF is essential for neonatal lung development (pulmonary vascular maturation), brain (angiogenesis in developing cortex), and kidney (glomerulogenesis) — systemic VEGF suppression in a premature neonate carries developmental risk

• Allows normal retinal vascularization to continue (laser destroys the peripheral avascular retina permanently)
• Lower risk of high myopia (laser-treated eyes have higher myopia rates)

4.6 Myopic Choroidal Neovascularization (myopic CNV)

• Lacquer cracks (breaks in Bruch's membrane)
• RPE atrophy
• CNV at the edge of lacquer cracks or atrophic areas

• Typically occurs in younger patients (20-50 years)
• The CNV is usually small and type 2 (classic, subretinal)
• Often responds well to a small number of anti-VEGF injections — many patients need only 1-3 injections total

4.7 Other Ophthalmic Uses

---

PART 5: RESISTANCE, SWITCHING, AND SUBOPTIMAL RESPONSE

5.1 Defining Suboptimal Response

1. Primary non-response: Persistent exudation despite adequate initial treatment (≥3 injections) — suggests the disease is not primarily VEGF-driven, or there are anatomical barriers
2. Secondary (acquired) resistance / tachyphylaxis: Initial response followed by declining efficacy over months-years, requiring increasing injection frequency with diminishing anatomical improvement
3. Pseudo-tachyphylaxis: Apparent resistance actually due to undertreatment (inadequate dosing intervals, missed injections, poor compliance)

• Persistent SRF and/or IRF on OCT despite ≥3 properly-timed injections
• Failure to extend the treatment interval beyond 4-6 weeks despite multiple attempts (TAE cannot be extended)
• Declining VA despite anatomical stability
• Progressive geographic atrophy despite treatment

5.2 Mechanisms of Resistance

1. Anti-drug antibodies (ADA): Neutralizing antibodies against ranibizumab or bevacizumab reduce free drug availability. More common with repeat injections.
2. VEGF-C/D escape pathway: Persistent exudation driven by VEGF-C and VEGF-D, which are not targeted by any agent except the experimental OPT-302. This is an escape mechanism after prolonged VEGF-A blockade.
3. PDGF-B upregulation: Platelet-derived growth factor-B can drive neovascularization independently of VEGF-A. This is the rationale for combining anti-VEGF with anti-PDGF in the 4D-150 gene therapy program.
4. Fibrotic remodeling: Longstanding CNV undergoes fibrotic transformation — the neovascular component becomes less VEGF-dependent, and sub-foveal fibrosis may cause permanent VA loss regardless of treatment.
5. Persistent Ang-2 activity: Residual vascular instability from Ang-2 despite VEGF-A neutralization — rationale for switching to faricimab.
6. Subretinal fluid (SRF) tolerance: Some authorities argue that a small amount of SRF (not IRF) may be acceptable in the context of stable VA — not all SRF requires aggressive retreatment.

5.3 Switching Strategy

• After ≥3 injections of the current agent with persistent exudation
• Inability to extend TAE interval beyond 6 weeks despite sustained treatment
• 2025 consensus recommendations (PMID 39824523): evidence-based indications for switching to faricimab include anti-VEGF fatigue, persistent fluid, and frequent reinjection requirements

• Faricimab: Most evidence-supported switch — adds Ang-2 blockade, addressing a mechanism untouched by VEGF-A monotherapy. AAO 2025 data: switching from bevacizumab/ranibizumab/aflibercept 2mg to faricimab showed anatomical improvement and interval extension in refractory cases.
• Aflibercept 8mg: Higher molar dose may overcome partial resistance driven by insufficient drug concentration; but switching from faricimab to AFL 8mg is less effective (54% ≥8w intervals vs. 70% when switching from AFL 2mg).
• Intravitreal corticosteroid (for DME): Dexamethasone implant or fluocinolone acetonide implant when inflammatory/non-VEGF mechanisms dominate.

---

PART 6: LANDMARK CLINICAL TRIALS — COMPLETE REFERENCE

6.1 Neovascular AMD

6.2 Diabetic Macular Edema

6.3 Retinal Vein Occlusion

6.4 PDR

6.5 ROP

---

PART 7: RECENT ADVANCES (2023-2026)

7.1 Faricimab — Real-World Data and Extended Use

• PMID 38233896 (review, 2024): Real-world evidence from multiple centres confirms faricimab's dual-inhibition delivers meaningful anatomical improvements, including in patients previously refractory to VEGF-A monotherapy.
• PMID 39824523 (BMJ Open Ophthalmol 2025): Canadian expert consensus on switching to faricimab — recommends switching after 3+ injections of current agent with persistent fluid or inability to extend intervals.
• Faricimab for RVO: BALATON (BRVO) and COMINO (CRVO) trials showed faricimab non-inferior to aflibercept for RVO-related ME; a 2025 review (PMID 41164764) summarizes emerging evidence. Faricimab for PCV: a 2025 meta-analysis (PMID 39548881) supports efficacy for polypoidal choroidal vasculopathy.
• 2025 network meta-analysis (PMID 40241463, Acta Ophthalmol): Faricimab and high-dose aflibercept emerge as efficacy leaders for nAMD among agents achieving extended dosing intervals.

7.2 Aflibercept 8 mg — Consolidating Evidence

• PULSAR 96-week results (Ophthalmology, August 2025): Confirmed durable non-inferiority of q12-16w dosing with aflibercept 8mg vs. AFL 2mg q8w over 2 years. Visual and anatomical outcomes sustained with substantially reduced injection burden.
• PHOTON (DME): ~80% of patients achieved q12-16w intervals; real-world IRIS Registry data confirms this is achievable outside trial settings.
• Practical note: AFL 8mg requires a slightly larger injection volume (0.07 mL vs. 0.05 mL) — patients should be counselled that transient IOP spikes may be slightly more pronounced.

7.3 Port Delivery System (PDS) — Continuous Drug Delivery

• Continuous, steady-state drug delivery — no peaks and troughs
• Refills every 24 weeks (twice yearly outpatient procedure)
• Eliminates monthly injection visits

7.4 Anti-VEGF Biosimilars — Expanding Global Access

• SB11 (ranibizumab biosimilar, Samsung Bioepis / Biogen): Phase 3 equivalence trial demonstrated equivalent VA and anatomical outcomes vs. Lucentis; equivalent safety profile.
• ABP 938 (aflibercept biosimilar, Amgen): Similar Phase 3 equivalence demonstrated.
• FYB201 (ranibizumab biosimilar, Formycon): Approved in EU.

7.5 OPT-302 — Targeting the VEGF-C/D Escape Pathway

7.6 Gene Therapy — From Science Fiction to Phase 3 Reality

7.6.1 Surabgene Lomparvovec / ABBV-RGX-314 (RegenxBio / AbbVie)

• Vector: AAV8 (naturally transduces RPE cells via subretinal injection)
• Transgene: Encodes a ranibizumab-like anti-VEGF Fab fragment
• Delivery routes: (1) Subretinal (surgical — via vitreoretinal surgery); (2) Suprachoroidal (in-office, via SCS Microinjector — simpler, non-surgical)
• Phase 1/2a (Lancet 2024, PMID 38554726): Dose-escalation subretinal delivery — all doses showed durable reduction in injection burden; higher doses achieved near-complete injection independence in some patients
• Phase 2 LUNA trial (2025 results, presented FLORetina December 2025): N=60, two doses with enhanced corticosteroid prophylaxis. 2-year results: mean annualized anti-VEGF injections reduced by ~89-90% (from ~10/year at baseline to 0.9-1.1 post-treatment); 46-61% of participants received ≤1 total injection cumulatively over 2 years
• Phase 3: ATMOSPHERE (subretinal delivery) and ASCENT (suprachoroidal delivery) trials — topline data expected Q4 2026 to H2 2027
• Note (retina-specialist.com, June 2026): All three gene therapy programs require corticosteroid prophylaxis (oral prednisolone tapering course) to manage AAV vector-induced inflammatory responses in the first weeks post-injection.

7.6.2 Ixoberogene Soroparvovec (Adverum Biotechnologies / Eli Lilly)

• Vector: Modified AAV2.7m8 (engineered capsid for efficient intravitreal delivery — no surgery required)
• Transgene: Encodes an aflibercept-based construct
• LUNA Phase 2 data (Adverum): 94% reduction in anti-VEGF injection burden; substantial VA and anatomical maintenance
• Corporate significance: Eli Lilly's acquisition of Adverum Biotechnologies in 2024 — the largest pharmaceutical company in the world betting on ocular gene therapy is a major commercial signal of confidence in the platform
• Phase 3: Pivotal trial ongoing; data expected H2 2027

7.6.3 4D-150 (4D Molecular Therapeutics)

• Vector: Proprietary AAV (R100 capsid) designed for efficient intravitreal delivery
• Dual transgene: Encodes both anti-VEGF Fab AND anti-PDGF-B DARPin (designed ankyrin repeat protein) — simultaneously blocking VEGF-A and PDGF-B
• Rationale for PDGF-B co-blockade: PDGF-B is a co-driver of neovascularization and pericyte recruitment; blocking both VEGF-A and PDGF-B may achieve superior and more durable vascular regression than VEGF-A alone
• Phase 2 data: ~80% reduction in injection burden; ongoing Phase 3 development

7.7 Emerging Delivery Platforms Beyond Gene Therapy

• CLS-AX (axitinib, a multi-target tyrosine kinase inhibitor): delivered into the suprachoroidal space via the SCS Microinjector (Clearside Biomedical); Phase 3 — single injection may provide 6 months of anti-VEGF effect
• Advantage: in-office, no surgery, targeted delivery to choroid and RPE

• GB-102 (sunitinib malate intravitreal suspension, Graybug Vision): Microparticle suspension providing 6-month release; early Phase trials
• KSI-301 (OPT-302 / anti-VEGF antibody-polymer conjugate, Kodiak Sciences): Phase 3 for AMD and DME — BEACON trial; prolonged retention in vitreous via polymer conjugation

• OCS-01 (dexamethasone/bevacizumab nanoemulsion) — Phase 2 for DME; highly limited bioavailability to retina remains the central challenge for topical delivery

7.8 OCT Biomarkers Predicting Anti-VEGF Response

• Presence of subretinal fluid (SRF) at baseline (more responsive to VEGF-A blockade than pure IRF)
• Intact ellipsoid zone (EZ) / inner segment-outer segment (IS/OS) junction — intact photoreceptors
• Intact external limiting membrane (ELM)
• Greater central macular thickness at baseline (more room for improvement)

• Disorganisation of retinal inner layers (DRIL) — structural biomarker of inner retinal damage; poor prognosis even with treatment
• Outer nuclear layer (ONL) thinning — photoreceptor loss already established
• Hyperreflective foci (HRF) — microglial/macrophage activation, lipid exudates; inflammatory component

---

PART 8: PRACTICAL CLINICAL DECISION FRAMEWORK

8.1 Choosing an Initial Agent (2026 Practice)

8.2 Monitoring Protocol (General Principle)

• Monthly OCT during loading phase and for at least the first 3 months of any new regimen
• VA and OCT at every visit — both measures together guide treatment decisions
• FFA/ICG: Not needed at every visit; useful for initial diagnosis (lesion characterization), suspected RPE tear, suspected PCV/RAP, or when OCT changes are unexplained
• OCT-A: Useful for visualizing CNV activity without dye injection; increasingly used for monitoring
• IOP measurement: At every anti-VEGF visit (especially if on long-term treatment or risk factors for sustained IOP elevation)

8.3 Treatment Duration and End-Points

• ≥2 years of complete quiescence (no SRF/IRF on OCT, stable VA) on maximally-extended interval
• Patient preference (burden, frailty, systemic comorbidities)

• nAMD: CNV can reactivate within weeks-months of stopping, especially type 1 and type 3 MNV. Most guidelines recommend indefinite monitoring even if treatment is suspended.
• DME: Metabolic improvement (HbA1c optimization, BP control) may allow treatment reduction; laser for extrafoveal microaneurysms can reduce anti-VEGF dependency.

---

KEY TAKE-HOME POINTS

1. VEGF-A, acting via VEGFR-2, is the primary molecular target in all major neovascular/exudative retinal diseases.
2. HIF-1α is the master upstream regulator — hypoxia drives it; it drives VEGF; VEGF drives pathological vessels.
3. Ang-2 is the key co-conspirator — faricimab's dual VEGF-A/Ang-2 blockade represents the most significant mechanistic advance since anti-VEGF began.
4. Anti-VEGF agents differ critically in molecular architecture (Fab, IgG, fusion protein, scFv, bispecific) — these differences determine binding affinity, duration of action, systemic safety, and dosing interval.
5. Intravitreal delivery is standard — maintains therapeutic concentrations while minimizing systemic exposure.
6. Start treatment within 2-3 weeks of symptom onset; better baseline VA = better final VA.
7. TAE is now the preferred dosing strategy across most diseases and agents.
8. Faricimab (q16w max) and Aflibercept 8mg (q12-16w) offer the longest treatment intervals currently available.
9. Brolucizumab achieves long intervals but carries a higher risk of vision-threatening intraocular inflammation.
10. Biosimilars (SB11, ABP 938) are clinically equivalent to originators and expanding global access.
11. Gene therapy Phase 3 trials (ABBV-RGX-314, ixoberogene, 4D-150) have topline data expected 2026-2027 — this may fundamentally change the treatment paradigm within the next decade.
12. Pregnancy: use intravitreal triamcinolone, not anti-VEGF.
13. ROP: ranibizumab preferred over bevacizumab for systemic safety; mandatory long-term follow-up for late recurrence.
14. OCT biomarkers (DRIL, EZ integrity, ONL thickness) predict treatment response — use them to set realistic VA expectations with patients.

---

• Kanski's Clinical Ophthalmology: A Systematic Approach, 10th edition (primary clinical reference throughout)
• The Wills Eye Manual, 8th edition
• Banerjee et al. Systemic effects of intravitreal anti-VEGF: Ophthalmol Ther 2025
• TENAYA/LUCERNE 2yr: Ophthalmology 2024 (PMID 38382813)
• YOSEMITE/RHINE 2yr DME: Ophthalmology 2024 (PMID 38158159)
• RGX-314 Phase 1/2a: Lancet 2024 (PMID 38554726)
• Biosimilars Cochrane 2024: Cochrane (PMID 38829176)
• Pagoda RCT (PDS/DME): JAMA Ophthalmol 2025 (PMID 40048197)
• ROP NMA: Surv Ophthalmol 2024 (PMID 38432359)
• RVO NMA: Surv Ophthalmol 2025 (PMID 40419166)
• nAMD comparative NMA: Acta Ophthalmol 2025 (PMID 40241463)
• DME OCT biomarkers: Ophthalmology 2026 (PMID 40803536)
• Faricimab Ang-2/VEGF dual role: Graefes 2025 (PMID 39708087)
• Gene therapy pipeline: retina-specialist.com June 2026
• AAO 2025 Intravitreal Injections Clinical Statement: AAO 2025

---

PART 2: ANTI-VEGF AGENTS — COMPARATIVE TABLES

Table 2A: Structural and Molecular Comparison

---

Table 2B: Pharmacokinetics Comparison

---

Table 2C: Dosing Regimens by Agent

---

Table 2D: Safety Profile Comparison

---

PART 6: LANDMARK CLINICAL TRIALS — COMPLETE REFERENCE TABLES

Table 6A: Neovascular AMD — Landmark Trials

---

Table 6B: Diabetic Macular Edema — Landmark Trials

---

Table 6C: Retinal Vein Occlusion — Landmark Trials

---

Table 6D: Proliferative Diabetic Retinopathy — Landmark Trials

---

Table 6E: Retinopathy of Prematurity — Landmark Trials

---

PART 7: RECENT ADVANCES — SUMMARY TABLES (2023-2026)

Table 7A: New and Extended-Indication Agents

---

Table 7B: Gene Therapy Pipeline (2024-2026)

---

Table 7C: Emerging Drug Targets Beyond VEGF-A

---

Table 7D: Novel Delivery Systems

---

Table 7E: Key Recent Publications (2023-2026)

---